Skip to main content
Top

22-06-2023 | Non-Hodgkin Lymphoma | Congress News | News

EHA 2023

Outcomes of axi-cel in daily practice consistent with ZUMA-5

MedNet.nl: The outcomes and safety of axicabtagene ciloleucel (axi-cel) in patients with relapsing or refractory follicular lymphoma appear to be consistent with the outcomes and safety observed in the ZUMA-5 study in daily practice, despite a broader patient population. 

Related topics

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine